REGENXBIO Inc. RGNX
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -50.28%
- 1 year
- -43.93%
- Open
- 7.27
- Prev close
- 7.20
- Mkt cap
- 472.65M
- Vol
- 1.03M
- Avg vol
- 1.36M
- EPS
- -3.78
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.04
- High
- 7.46
- Forward P/E
- -6.83
- Beta
- 1.23
- Short ratio
- 6.02
- Inst. own
- 92.34%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 9.58
- 200-d avg
- 13.24
- 1y target
- 37.64
5D chart
Signals (90)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 4:00 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 3:55 PM | 2 hours ago |
| RSI: Overbought | Nov 2, 3:45 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 2:35 PM | 3 hours ago |
| SMA: Bullish | Nov 2, 2:35 PM | 3 hours ago |
| SMA: Bearish | Nov 2, 2:30 PM | 3 hours ago |
| MACD: Buy Signal | Nov 2, 2:00 PM | 4 hours ago |
| MACD: Sell Signal | Nov 2, 1:30 PM | 4 hours ago |
| SMA: Bearish | Nov 2, 1:10 PM | 5 hours ago |
| SMA: Bullish | Nov 2, 1:05 PM | 5 hours ago |
| MACD: Buy Signal | Nov 2, 1:05 PM | 5 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 5 hours ago |
| MACD: Sell Signal | Nov 2, 12:20 PM | 5 hours ago |
| MACD: Buy Signal | Nov 2, 11:50 AM | 6 hours ago |
| SMA: Bullish | Nov 2, 11:30 AM | 6 hours ago |
| SMA: Bearish | Nov 2, 10:50 AM | 7 hours ago |
| MACD: Sell Signal | Nov 2, 10:40 AM | 7 hours ago |
| SMA: Bearish | Nov 2, 10:30 AM | 7 hours ago |
| SMA: Bullish | Nov 2, 10:20 AM | 7 hours ago |
| SMA: Bearish | Nov 2, 10:15 AM | 7 hours ago |
| RSI: Overbought | Nov 2, 9:55 AM | 8 hours ago |
| RSI: Overbought | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 5 days ago |
| RSI: Overbought | Oct 28, 2:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:25 PM | 5 days ago |
| RSI: Overbought | Oct 28, 2:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 5 days ago |
| RSI: Overbought | Oct 28, 1:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 5 days ago |
| RSI: Overbought | Oct 28, 12:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:45 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 6 days ago |
News
4 days ago zacks.com
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago prnewswire.com
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m.
1 week ago defenseworld.net
Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR)
REGENXBIO (NASDAQ: RGNX - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two…
1 week ago marketbeat.com
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
REGENXBIO NASDAQ: RGNX outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or…
1 week ago seekingalpha.com
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript
3 weeks ago prnewswire.com
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ --…
4 weeks ago benzinga.com
Full Transcript: Regenxbio Q2 2026 Earnings Call
Regenxbio (NASDAQ:RGNX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For…
-
4 weeks ago benzinga.com
Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22
Mizuho analyst Graig Suvannavejh initiates coverage on Regenxbio (NASDAQ:RGNX) with a Outperform rating and announces Price Target of $22.
-
1 month ago benzinga.com
Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening Events
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no…
1 month ago prnewswire.com
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no…
-
1 month ago benzinga.com
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement") with Sarepta
1 month ago seekingalpha.com
REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago prnewswire.com
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved…
2 months ago gurufocus.com
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its offi
2 months ago businesswire.com
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against…
2 months ago zacks.com
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $21
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $23 to $21.
2 months ago seekingalpha.com
Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity
Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone…
2 months ago gurufocus.com
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli PR Newswire ROCKVILLE, Md., Aug. 25, 20
2 months ago prnewswire.com
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
-
2 months ago benzinga.com
Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.
2 months ago globenewswire.com
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares…
2 months ago benzinga.com
Crude Oil Down 3%; XPeng Shares Fall After Q2 Results
US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected…
2 months ago barrons.com
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.
2 months ago benzinga.com
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold
Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings…
2 months ago reuters.com
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
Regenxbio said on Monday the U.S. Food and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal scans found abnormalities in five study…
-
2 months ago benzinga.com
The FDA Places Clinical Hold On Regenxbio's RGX-121 Following Asymptomatic Spine MRI Findings In Five Participants In CAMPSIITE Study In Mucopolysaccharidosis Type II Patients
REGENXBIO Inc. (NASDAQ:RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known…
2 months ago prnewswire.com
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of…
2 months ago seekingalpha.com
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)
Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027…
2 months ago benzinga.com
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $23
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $26 to $23.
2 months ago benzinga.com
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
Wall Street analysts changed outlook on top names. For rating changes, check our analyst ratings page. See analysts' views on ADIG, TSEM and more
2 months ago benzinga.com
This HubSpot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top Wall Street analysts changed outlook on top names. For all changes & stock ratings, see analyst ratings page. Some stocks downgraded & price targets lowered.
-
2 months ago benzinga.com
Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12
Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:RGNX) from Overweight to Equal-Weight and maintains the price target from $12 to $12.
-
2 months ago benzinga.com
Regenxbio Q2 EPS $0.43 Beats $(0.03) Estimate, Sales $108.019M Miss $117.127M Estimate
Regenxbio (NASDAQ:RGNX) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $(0.03) by 1533.33 percent. This is a 131.16 percent increase over losses of…
3 months ago benzinga.com
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.
3 months ago benzinga.com
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments
REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.
3 months ago benzinga.com
Crude Oil Surges 4%; Travelers Posts Upbeat Q2 results
Nasdaq falls over 200 points, Dow down 0.28%, S&P 500 drops 0.51%. Energy shares up 1.4%, communication services stocks down 3.1%. Travelers Companies beats Q2 estimates. Southland Holdings up 51%,…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics…
3 months ago benzinga.com
Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings beat estimates. Other stocks also falling in pre-market.
-
3 months ago benzinga.com
Market-Moving News for July 17th
NFLX: 10% | Netflix shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 guidance below estimates. Also, the company narrowed its FY26 sales guidance…
-
3 months ago benzinga.com
REGENXBIO Prices Offering Of 10,003,889 Shares At $9.00 Per Share And 1,111,111 Pre-Funded Warrants At $8.9999 Per Warrant
The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by REGENXBIO, are expected to be approximately…
3 months ago benzinga.com
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partnership with Alabama State University.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased…
-
3 months ago benzinga.com
REGENXBIO Plans To Commence $100M Common Stock Offering
REGENXBIO Inc. (NASDAQ:RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering. The offering is…
-
4 months ago benzinga.com
REGENXBIO Announces First Patient Dosed In Phase IIb/III NAAVIGATE Clinical Trial Of Investigational Surabgene Lomparvovec In Diabetic Retinopathy Using Suprachoroidal Delivery; REGENXBIO To Receive $100M From Abbvie For This Milestone
New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026ROCKVILLE, Md., June 29, 2026 /PRNewswire/ -- REGENXBIO Inc.…
4 months ago benzinga.com
What's Going On With Capricor Therapeutics Stock On Friday?
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its Duchenne muscular dystrophy therapy.